T1	p 70 114	of acute nonlymphocytic leukemia in adults .
T2	p 155 162	( INN :
T3	p 390 401	maintenance
T4	p 419 456	adult acute nonlymphocytic leukemia (
T5	p 518 528	, patients
T6	p 628 648	101 eligible cases (
T7	p 927 949	the 15-49 yr age group
T8	p 955 977	the 50-65 yr age group
T9	p 1061 1083	immunotherapy of adult
T10	p 1151 1167	elderly patients
T11	i 37 69	chemoimmunotherapy with bestatin
T12	i 121 171	immunomodulating agent , bestatin ( INN : Ubenimex
T13	i 337 374	bestatin immunotherapy in combination
T14	i 380 389	remission
T15	i 402 414	chemotherapy
T16	i 552 560	bestatin
T17	i 590 591	)
T18	i 658 662	: 48
T19	i 673 674	:
T20	i 700 708	bestatin
T21	i 879 887	bestatin
T22	i 1008 1016	Bestatin
T23	o 73 102	acute nonlymphocytic leukemia
T24	o 146 154	bestatin
T25	o 281 289	response
T26	o 431 445	nonlymphocytic
T27	o 499 517	complete remission
T28	o 582 584	os
T29	o 724 740	longer remission
T30	o 803 813	survival .
T31	o 826 851	prolongation of remission
T32	o 1114 1136	survival and remission
T33	o 1192 1193	.